forecast
Argenx's first drug is a prototype for pipeline expansion
Investors are watching whether Argenx's highly de-risked first drug approach repeats in other pipeline drugs, since a second promising readout suggests the platform may generalize across diseases and partnerships in oncology.
forecastpending
Speaker
JuliaEvidence Quote
“they just had actually a very good and promising readout from their second drug”
Created: 11/17/2026, 3:39:21 AM
Your notes
Loading notes...